Implantable device could allow doctors to test cancer drugs in patients before prescribing chemotherapy
More than 100 drugs have been approved to treat cancer, but predicting which ones will help a particular patient is an inexact science at best.
A new device developed at MIT may change that. The implantable device, about the size of the grain of rice, can carry small doses of up to 30 different drugs. After implanting it in a tumor and letting the drugs diffuse into the tissue, researchers can measure how effectively each one kills the patient’s cancer cells.
Such a device could eliminate much of the guesswork now involved in choosing cancer treatments, says Oliver Jonas, a postdoc at MIT’s Koch Institute for Integrative Cancer Research and lead author of a paper describing the device in the April 22 online edition of Science Translational Medicine.
“You can use it to test a patient for a range of available drugs, and pick the one that works best,” Jonas says.
The paper’s senior authors are Robert Langer, the David H. Koch Professor at MIT and a member of the Koch Institute, the Institute for Medical Engineering and Science, and the Department of Chemical Engineering; and Michael Cima, the David H. Koch Professor of Engineering at MIT and a member of the Koch Institute and the Department of Materials Science and Engineering.
Putting the lab in the patient
Most of the commonly used cancer drugs work by damaging DNA or otherwise interfering with cell function. Recently, scientists have also developed more targeted drugs designed to kill tumor cells that carry a specific genetic mutation. However, it is usually difficult to predict whether a particular drug will be effective in an individual patient.
In some cases, doctors extract tumor cells, grow them in a lab dish, and treat them with different drugs to see which ones are most effective. However, this process removes the cells from their natural environment, which can play an important role in how a tumor responds to drug treatment, Jonas says.
“The approach that we thought would be good to try is to essentially put the lab into the patient,” he says. “It’s safe and you can do all of your sensitivity testing in the native microenvironment.”
The device, made from a stiff, crystalline polymer, can be implanted in a patient’s tumor using a biopsy needle. After implantation, drugs seep 200 to 300 microns into the tumor, but do not overlap with each other. Any type of drug can go into the reservoir, and the researchers can formulate the drugs so that the doses that reach the cancer cells are similar to what they would receive if the drug were given by typical delivery methods such as intravenous injection.
After one day of drug exposure, the implant is removed, along with a small sample of the tumor tissue surrounding it, and the researchers analyze the drug effects by slicing up the tissue sample and staining it with antibodies that can detect markers of cell death or proliferation.
Ranking cancer drugs
To test the device, the researchers implanted it in mice that had been grafted with human prostate, breast, and melanoma tumors. These tumors are known to have varying sensitivity to different cancer drugs, and the MIT team’s results corresponded to those previously seen differences.
The researchers then tested the device with a type of breast cancer known as triple negative, which lacks the three most common breast cancer markers: estrogen receptor, progesterone receptor, and Her2. This form of cancer is particularly aggressive, and none of the drugs used against it are targeted to a specific genetic marker.
Using the device, the researchers found that triple negative tumors responded differently to five of the drugs commonly used to treat them. The most effective was paclitaxel, followed by doxorubicin, cisplatin, gemcitabine, and lapatinib. They found the same results when delivering these drugs by intravenous injection, suggesting that the device is an accurate predictor of drug sensitivity.
The Latest on: Personalized medicine
via Google News
The Latest on: Personalized medicine
- Safer and more affordable medicine for all? How Pharmacogenomics may level the playing fieldon January 30, 2020 at 10:34 pm
A trained molecular biologist, immunologist, and the former Head of Genomics Science and Biologics at Sanofi, Tocci has worked in drug discovery and pre-clinical development for most of his career, ...
- New resources in precision medicine that every doctor should know abouton January 29, 2020 at 8:12 am
Precision medicine, or personalized medicine as it is sometimes referred to, is a most significant and promising healthcare trend. The National Institutes of Health (NIH) defines precision medicine as ...
- Global Personalized Medicine Market 2020-Laboratory Corporation of America,Quest Diagnostics,Abbott, Becton Dickinson and Coon January 29, 2020 at 2:49 am
Eon Market Research has announced the inclusion of a new market research report to its comprehensive collection of research studies. The 115-page research report, titled "Global Personalized Medicine ...
- Genomic Profiling for Precision Medicine: Interview with David Spetzler, Caris Life Scienceson January 28, 2020 at 1:54 pm
Personalized medicine holds enormous potential in improving patient outcomes, but has been limited by the complexity of contextualizing the molecular or genetic signatures of diseased tissues, such as ...
- Direct-to-consumer genetic tests attempt to capture the zeitgeist of personalized medicineon January 28, 2020 at 3:06 am
We are practicing medicine at the intersection of expectation and limitation ... holistic guidance — and deliver what we as clinicians know is truly personalized care.
- Researchers identify opportunities to advance genomic medicineon January 27, 2020 at 1:52 pm
Cho, MD, Dean of Translational Genetics at the Icahn School of Medicine at Mount Sinai, Director of The Charles Bronfman Institute for Personalized Medicine, and a co-author of the report. "Applying ...
- Addressing Disparities Will Advance Genomics, Precision Medicineon January 27, 2020 at 7:53 am
Cho, MD, Dean of Translational Genetics at the Icahn School of Medicine at Mount Sinai, Director of The Charles Bronfman Institute for Personalized Medicine, and a co-author of the report. “Applying ...
- Artificial Intelligence in Medicine Market Advanced Technology and New Innovations by 2025 – InSilico Medicine, Globavir Bioscienceson January 27, 2020 at 5:02 am
Based on application, the market is categorized into drug discovery & repurposing, clinical research trial, personalized medicine, and others. Based on region, it is analyzed across North America, ...
- Are intestinal organoids the key to developing personalized therapy for cystic fibrosis?on January 27, 2020 at 2:18 am
“An organoid-assay-based personalized medicine approach offers the potential of a new decision-supporting technology to inform clinical decisions and provide each patient with CFTR modulators that ...
- Global Personalized Medicine Market revenue to hit USD 3466 Million By 2024on January 24, 2020 at 1:29 am
Zion Market Research added a new report "Global Personalized Medicine Market Set For Rapid Growth To Reach Around USD 3466 Million By 2024" in its database, which provides an expert and in-depth ...
via Bing News